- cafead   Nov 22, 2022 at 11:22: AM
via The US Food and Drug Administration (FDA) has approved Legend Biotech’s Investigational New Drug (IND) application to proceed with LB2102’s clinical development for treating extensive stage small cell lung cancer (SCLC).
article source
article source